TruAlt Bioenergy Q2 FY27 Earnings Call Transcript Released
TruAlt Bioenergy reported Q2 FY27 revenue of ₹811 crore, up 606% YoY. H1 FY27 revenue reached ₹1,438 crore, up 243% YoY. Q2 FY27 PAT was ₹35 crore, a turnaround from a loss. The company aims to increase ethanol capacity utilization to 75-80% and is expanding its CBG business with new plants and government incentives. Capex for SAF is planned pending policy clarity.
The announcement details significant financial performance improvements (revenue growth, profitability turnaround), strategic business expansions (CBG, SAF), and operational updates in the core ethanol business. These factors have a material impact on the company's financial health and future growth prospects.
The company reported significant year-on-year revenue growth and a turnaround in profitability, indicating positive financial performance and operational improvements. The expansion plans in CBG and ongoing ethanol operations, coupled with positive outlooks on capacity utilization and government support, contribute to a positive sentiment.
TruAlt Bioenergy Limited has released the transcript of their Earnings Conference Call held on October 26, 2026, to discuss the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026.
During the call, Managing Director Mr. Vijaykumar Murugesh Nirani reported growth in revenue numbers for Q2 FY27, though margins experienced shrinkage due to increased raw material prices. He highlighted an increased ethanol allocation of 40 crore liters for the last ethanol supply year, leading to an average capacity utilization of 65-70%. Looking ahead, the company aims for 75-80% capacity utilization. The next ethanol supply year tender (2026-2027) is out, with a ban on sugarcane juice and B-heavy molasses for ethanol production, which is expected to put pressure on grains and C-heavy molasses.
In the CBG segment, the first plant under the joint venture with Sumitomo Corporation is being ramped up, with two more plants to be commissioned within the current quarter, bringing the total CBG operating plants to four. By the end of the quarter, installed CBG production capacity is expected to reach 72 metric tons per day. The company also plans to start construction of additional units with GAIL, anticipating significant growth from the CBG business due to government incentives under the GOBARdhan policy.
For the sustainable aviation fuel (SAF) business, front-end engineering is ongoing, but the roadmap and incentive policy are still awaited from the government. The company has received an incentive of ₹150 crore as viability gap funding under the PM JI-VAN Yojana for the proposed SAF plant.
In the fuel retail business, seven outlets are operational, with more nearing commissioning. However, due to crude price volatility, further expansion of outlets is being slowed down. The company has completed all proposed capex for the ethanol business and will focus on increasing capacity utilization and improving margins.
CFO Mr. Anand Kishore presented the financials, stating that revenue from operations for Q2 FY27 stood at ₹811 crore, a 606% year-on-year growth from ₹115 crore in Q2 FY26. For H1 FY27, revenue was ₹1,438 crore, a 243% growth from ₹419 crore in H1 FY26. EBITDA for Q2 FY27 was ₹114 crore (14.03% margin), and for H1 FY27, it was ₹261 crore (18.2% margin). Profit Before Tax (PBT) for Q2 FY27 was ₹47 crore, a significant turnaround from a loss of ₹49 crore in Q2 FY26. Profit After Tax (PAT) for Q2 FY27 was ₹35 crore, compared to a loss of ₹38 crore in the previous year. For H1 FY27, PAT was ₹94 crore, against a loss of ₹33 crore in H1 FY26. The company generated ₹192 crore in cash flow from operating activities during H1 FY27 and invested ₹180 crore in capex. Total equity stood at ₹1,687 crore as of September 30, 2026, with a debt-to-equity ratio of 0.55x. Inventory reduced from ₹528 crore to ₹206 crore, and trade receivables reduced from ₹406 crore to ₹367 crore.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.